WO1993022433A3 - Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament - Google Patents

Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament Download PDF

Info

Publication number
WO1993022433A3
WO1993022433A3 PCT/DE1993/000374 DE9300374W WO9322433A3 WO 1993022433 A3 WO1993022433 A3 WO 1993022433A3 DE 9300374 W DE9300374 W DE 9300374W WO 9322433 A3 WO9322433 A3 WO 9322433A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
viruses
animals
human beings
retro
Prior art date
Application number
PCT/DE1993/000374
Other languages
German (de)
French (fr)
Other versions
WO1993022433A2 (en
Inventor
Frank Andreas Harald Meyer
Original Assignee
Frank Andreas Harald Meyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frank Andreas Harald Meyer filed Critical Frank Andreas Harald Meyer
Priority to EP93911729A priority Critical patent/EP0677103A1/en
Publication of WO1993022433A2 publication Critical patent/WO1993022433A2/en
Publication of WO1993022433A3 publication Critical patent/WO1993022433A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • C12N9/1276RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae

Abstract

Some diseases in the bodies of human beings and animals are caused by viruses. Many retro-viruses carry carcinogens. Attempts have so far been made to interfere with complete retro-viruses to combat retro-viruses. The drawbacks of the prior art therapy are that various kinds of side-effects which are uncomfortable for the patient are inevitable and that the course of many diseases is slowed down but the disease cannot be cured. The novel medicament is especially suitable for blocking virus multiplication and carcinogens. The medicament contains virus shells which attach themselves to the receptors of the known basic cells. The medicament comprises cells taken from the organism which have been treated with anti-viruses. The medicament comprises cells taken from the organism which have been treated with the appropriate glycolysed liposomes. When the medicament is used, the patients treated suffer from hardly any uncomfortable side-effects and diseases are cured.
PCT/DE1993/000374 1992-04-28 1993-04-28 Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament WO1993022433A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP93911729A EP0677103A1 (en) 1992-04-28 1993-04-28 Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ATPCT/EP92/00923 1992-04-28
EP9200923 1992-04-28
DE4238879 1992-11-19
DEP4238879.1 1992-11-19

Publications (2)

Publication Number Publication Date
WO1993022433A2 WO1993022433A2 (en) 1993-11-11
WO1993022433A3 true WO1993022433A3 (en) 1994-07-07

Family

ID=25920549

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1993/000374 WO1993022433A2 (en) 1992-04-28 1993-04-28 Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament

Country Status (2)

Country Link
AU (1) AU4259193A (en)
WO (1) WO1993022433A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650370A4 (en) * 1992-06-08 1995-11-22 Univ California Methods and compositions for targeting specific tissue.
DE19503082A1 (en) * 1995-02-01 1996-08-08 Univ Ludwigs Albert Subject and method for preferentially transient expression and possible translation of specific RNA in the cytoplasmic region of higher eukaryotic cells

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240332A2 (en) * 1986-04-02 1987-10-07 Pioneer Hi-Bred International, Inc. Virus resistant plants having antisense RNA
EP0278667A2 (en) * 1987-02-09 1988-08-17 Mycogen Plant Science, Inc. Hybrid RNA virus
WO1990005538A1 (en) * 1988-11-14 1990-05-31 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Parvovirus capsids
EP0387775A1 (en) * 1989-03-16 1990-09-19 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Genetic construct for inhibiting RNA function
WO1990012087A1 (en) * 1989-04-05 1990-10-18 Novacell Corporation Infectious targetted replication-defective virion
WO1992005266A2 (en) * 1990-09-21 1992-04-02 Viagene, Inc. Packaging cells
WO1992006180A1 (en) * 1990-10-01 1992-04-16 University Of Connecticut Targeting viruses and cells for selective internalization by cells

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240332A2 (en) * 1986-04-02 1987-10-07 Pioneer Hi-Bred International, Inc. Virus resistant plants having antisense RNA
EP0278667A2 (en) * 1987-02-09 1988-08-17 Mycogen Plant Science, Inc. Hybrid RNA virus
WO1990005538A1 (en) * 1988-11-14 1990-05-31 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Parvovirus capsids
EP0387775A1 (en) * 1989-03-16 1990-09-19 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Genetic construct for inhibiting RNA function
WO1990012087A1 (en) * 1989-04-05 1990-10-18 Novacell Corporation Infectious targetted replication-defective virion
WO1992005266A2 (en) * 1990-09-21 1992-04-02 Viagene, Inc. Packaging cells
WO1992006180A1 (en) * 1990-10-01 1992-04-16 University Of Connecticut Targeting viruses and cells for selective internalization by cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GAREIS, M. ET AL.: "Homologous recombination of exogenous DNA fragments with genomic DNA in somatic cells of mice", CELLULAR AND MOLECULAR BIOLOGY, vol. 37, no. 2, 1991, pages 191 - 203, XP000406056 *

Also Published As

Publication number Publication date
WO1993022433A2 (en) 1993-11-11
AU4259193A (en) 1993-11-29

Similar Documents

Publication Publication Date Title
AU8335291A (en) Drugs, their manufacture, and their use as painkillers and/or to treat inflammations in humans and animals
CA2214503A1 (en) Method for treating tumors
IL105366A0 (en) Methods and compositions for the treatment of diseases with interferon while reducing side effects
PT668763E (en) USE OF FENSERIN FOR THE PREPARATION OF MEDICINES TO TREAT DISEASES OF KNOWLEDGE
ZA95679B (en) Products containing G-CSF and TNF binding protein
DE3650505T2 (en) AICA riboside for the prophylactic treatment of diseases with reduced blood flow.
WO1993022433A3 (en) Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament
DE69007065D1 (en) Use of diadenosine 5 ', 5' '' - p1, p4-tetraphosphate for the manufacture of a medicament for the treatment of heart diseases.
GB8917323D0 (en) Methods and pharmaceutical compositions for the treatment of ophthalmic diseases
US5547672A (en) Accelerated wound healing
GR3032224T3 (en) Therapeutic agent for threatened abortion.
AU5643299A (en) Humic acid and its use in the treatment of various conditions
HK1042239A1 (en) Bupropion to treat viral diseases.
EP0668771A4 (en) Treatment of autoimmune diseases by inducing tolerance to cells, tissues and organs.
RU94006478A (en) METHOD OF LIGHT THERAPY
Aliev et al. The possibility of the use of interferon in the treatment of alcoholism.
RU92011168A (en) PREPARATION FOR THE TREATMENT OF GYNECOLOGICAL DISEASES
RU2002131990A (en) METHOD FOR TREATING VICTIMS OF A CRANIO-BRAIN INJURY IN THE EARLY POST-TRAUMATIC PERIOD
ZA938915B (en) Treatment of viral infections by conjunctive therapy with acyclovir-like compounds and a 2'-vynyl substituted nucleoside analog
FARSHATOV The role of radioprotectors in the effectiveness of the treatment of combined radiation injuries(Vliianie radioproektorov na effektivnost' lecheniia kombinirovannykh radiatsionnykh porazhenii(Obzor literatury))
RU94043033A (en) Method of immunohomeostasis correction and modulation at viscera organs and nervous system sickness
MD197G2 (en) Preparation and method for hypogalactia treatment
Juca et al. Antimicrobial therapy with cefoxitin sodium in vascular surgery and angiology: Clinical and laboratorial survey.
RU94002713A (en) Method for treating children possessing elongated qt interval syndrome
RU92011195A (en) METHOD FOR REDUCING THE DOSE OF CHEMICAL DRUGS USED TO TREAT INFECTIOUS DISEASES IN SIMULTANEOUSLY IMPROVING THEIR THERAPEUTIC EFFICIENCY

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CZ DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR BY CA CH CZ DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: CA

WWE Wipo information: entry into national phase

Ref document number: 1993911729

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993911729

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1993911729

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993911729

Country of ref document: EP